Common problems in outpatient management of patients with diabetes in the age of insulin analogues

Primary Care - Clinics in Office Practice

Volumn 30, Issue 3, 2003, Pages 543-556

  DeWitt, Dawn E ^a,b   Dugdale, David C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

DIABETES INSIPIDUS; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG USE; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0141652801     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00037-X     Document Type: Review

References (33)

1. American Diabetes Association. Clinical practice recommendations - 2002. Diabetes Care 2002;25(Suppl 1):S1-147.
2. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
3. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75.
4. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. JAMA 2002;287:2504-5.
5. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
6. United Kingdom Prospective Diabetes Study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes: a multicenter study. Diabetes 1985;34:793-8.
7. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
8. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389-96.
9. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
10. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
11. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus: implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med 1996;124(1 Pt 2):131-5.
12. The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial, Am J Med 1991;90:450-9.
13. Fanelli CG, Pampanelli S, Porcellati F, et al. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in Type I diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. Ann Intern Med 2002;136:504-14.
14. Francis AJ, Home PD, Hanning I, et al. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) 1983;286:1173-6.
15. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.
16. Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985;290:105-8.
17. Sackey AH, Jefferson IG. Interval between insulin injection and breakfast in diabetes. Arch Dis Child 1994;71:248-50.
18. Jehle PM, Micheler C, Jehle DR, et al. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 1999;354:1604-7.
19. Annuzzi G, Del Prato S, Arcari R, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis 2001;11:168-75.
20. Colombel A, Murat A, Krempf M, et al. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999;16:319-24.
21. Bastyr EJ 3rd, Johnson ME, Trautmann ME, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-14.
22. Rabasa-Lhoret R, Bourque J, Ducros F, et al. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001;24:625-30.
23. Tuominen JA, Karonen SL, Melamies L, et al. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995;38:106-11.
24. Pfutzner A, Kustner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996;104:25-30.
25. Renner R, Pfutzner A, Trautmann M, et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999;22:784-8.
26. Melki V, Renard E, Lassmann-Vague V, et al. Improvement of HbAlc and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-82.
27. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77.
28. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998;21:1904-9.
29. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002;19:393-9.
30. Taylor R, Davies R, Fox C, et al. Appropriate insulin regimens for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000;23:1612-8.
31. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
32. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001;18:619-25.
33. Malone JK, Woodworth JR, Arora A, et al. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000;22:222-30.